{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:54:51Z","timestamp":1790024091772,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The BSRBR-RA"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to evaluate if and how the incidence of serious infection (SI) and active tuberculosis (TB) differ among seven biologic DMARDs (bDMARDs) in patients with RA considering the line of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with RA from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) cohort who initiated etanercept, certolizumab, infliximab, adalimumab, abatacept, rituximab or tocilizumab from the first to fifth line of therapy were included. Follow-up extended up to 3\u2009years. The primary outcome was SI and the secondary outcome was TB. Event rates were calculated and compared using Cox proportional hazards models, controlling for confounding with inverse probability of treatment weights. Comparisons were made overall and stratified by line of therapy. Sensitivity analysis was restricted to all treatment courses from 2009 (tocilizumab availability) until the end of the study (2018).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 33\u2009897 treatment courses (62\u2009513 patient-years) the incidence of SI was 4.4\/100 patient-years (95% CI 4.2, 4.5). After adjustment, hazards ratios (HRs) of SI were slightly higher with adalimumab and infliximab compared with etanercept. However, no clear pattern was observed when stratifying by line of therapy in terms of incidence rate or HR. Sensitivity analyses showed similar HRs among these treatments. Regarding TB, all 49 cases occurred during the first three lines of treatment and rarely since 2009.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The risk of serious infections does not appear to be influenced by the line of therapy in patients with RA. However, the risk of TB seems to be more frequent during the initial lines of treatment or prior to 2009.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead515","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T23:41:20Z","timestamp":1695858080000},"page":"1957-1964","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of serious infections, including <i>Mycobacterium tuberculosis<\/i>, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-9009","authenticated-orcid":false,"given":"Kim","family":"Lauper","sequence":"first","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre , Manchester, UK"},{"name":"Division of Rheumatology, Geneva University Hospitals and Geneva Centre for Inflammation Research, Faculty of Medicine, University of Geneva , Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley-Fleet","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James B","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre of Rheumatic Disease, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath D","family":"Watson","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BSRBR-RA Contributors Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre , Manchester, UK"},{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"2024070114084059400_kead515-B1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2024070114084059400_kead515-B2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2024070114084059400_kead515-B3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024070114084059400_kead515-B5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Care Res"},{"key":"2024070114084059400_kead515-B6","first-page":"354","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"2024070114084059400_kead515-B7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024070114084059400_kead515-B8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emph","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"2024070114084059400_kead515-B9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B11","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1002\/art.23050","article-title":"Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor \u03b1 antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024070114084059400_kead515-B12","first-page":"CD008794","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2024070114084059400_kead515-B13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"Van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B14","doi-asserted-by":"crossref","first-page":"annrheumdis-2017-212825","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B15","first-page":"iv42","article-title":"The British Society for Rheumatology biologics register","volume":"64(Suppl 4)","author":"Watson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2024070114084059400_kead515-B17","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","article-title":"Avoiding pitfalls when combining multiple imputation and propensity scores","volume":"38","author":"Granger","year":"2019","journal-title":"Stat Med"},{"key":"2024070114084059400_kead515-B18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-\u03b1 treatment","volume":"60","author":"Ormerod","year":"2005","journal-title":"Thorax"},{"key":"2024070114084059400_kead515-B20","doi-asserted-by":"publisher","author":"National Collaborating Centre for Chronic Conditions","year":"2006","DOI":"10.1016\/j.jhin.2006.06.003"},{"key":"2024070114084059400_kead515-B21","article-title":"NICE guideline: Tuberculosis (NG33)","volume":"178","author":"NICE","year":"2016","journal-title":"Natl Inst Heal Care Excell"},{"key":"2024070114084059400_kead515-B22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070114084059400_kead515-B24","first-page":"2096","article-title":"Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register \u2014 rheumatoid arthritis","volume":"57","author":"Subesinghe","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"2024070114084059400_kead515-B25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/acr.23328","article-title":"Trends in hospitalizations for serious infections in patients with rheumatoid arthritis in the US between 1993 and 2013","volume":"70","author":"Jinno","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024070114084059400_kead515-B26","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","article-title":"Evaluation of the RABBIT risk score for serious infections","volume":"73","author":"Zink","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead515\/52241751\/kead515.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1957\/58378290\/kead515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1957\/58378290\/kead515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:59:45Z","timestamp":1719856785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/7\/1957\/7284107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead515","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,9,27]]}}}